We committed to developing preventative medicines and treatments for COVID-19 as soon as it was known as a pandemic. Successfully fighting it requires global partnerships among countries, companies, and more.
Here at Merck, we are also studying other approaches to ending the COVID-19 pandemic, including treatments and preventative medicines that are not vaccines. We are optimistic our industry’s efforts will create new treatments at a faster rate to fight this pandemic.
The rise of the COVID-19 pandemic has highlighted how much communities of color can be overly impacted by global health issues. We must learn how safe and effective (how well they work) our treatments are for all people around the world.
We’ve taken steps to close diversity gaps in our clinical trials, including to:
Diversity is important to us. That’s why, at Merck, we’ll continue to foster discussion, create awareness, and empower research sites to recruit patients based on the impact of diseases in groups that might otherwise be under-represented in our research.